Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.226
No. of companies carrying out R&D in Biotechnology;250 or more employees;122
No. of companies carrying out R&D in Biotechnology;Total 2021;1.348
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;30,5
%Companies according to biotechnology used: Genetic code;250 or more employees;36
%Companies according to biotechnology used: Genetic code;Total 2021;31
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;37,6
%Companies according to biotechnology used: Functional units;250 or more employees;46,7
%Companies according to biotechnology used: Functional units;Total 2021;38,4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;20,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;33,6
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2021;21,7
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48,6
%Companies according to biotechnology used: Bioprocesses;250 or more employees;68,1
%Companies according to biotechnology used: Bioprocesses;Total 2021;50,3
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;7,2
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;18
%Companies according to biotechnology used: Sub-cellular organisms;Total 2021;8,2
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;24
%Companies according to biotechnology used: Bio-computing;250 or more employees;25,4
%Companies according to biotechnology used: Bio-computing;Total 2021;24,1
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;11,8
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;11,5
%Companies according to biotechnology used: Nanobiotechnology;Total 2021;11,8
%Companies according to biotechnology used: Other;Fewer than 250 employees;17
%Companies according to biotechnology used: Other;250 or more employees;10,7
%Companies according to biotechnology used: Other;Total 2021;16,4
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;639
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;22
Companies in which biotechnology activities are: Main and/or exclusive;Total 2021;661
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;166
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;22
Companies in which biotechnology activities are: A secondary line of business;Total 2021;188
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;421
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;78
Companies in which biotechnology activities are: A tool necessary for production;Total 2021;500
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45,8
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;45,9
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total 2021;45,8
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;15,6
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;11,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2021;15,3
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;31,5
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;32
%Company by field(s) of ultimate application of biotechnology use: Food products;Total 2021;31,5
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;19,6
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2021;23,7
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;16
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;11,5
%Company by field(s) of ultimate application of biotechnology use: Environment;Total 2021;15,5
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13,4
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;13,1
%Company by field(s) of ultimate application of biotechnology use: Industry;Total 2021;13,4
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;10.473
Personnel in R&D in biotechnology (no. of persons);250 or more employees;5.271
Personnel in R&D in biotechnology (no. of persons);Total 2021;15.744
Personnel in R&D in biotechnology (no. of persons): Research personnel;Fewer than 250 employees;5.914
Personnel in R&D in biotechnology (no. of persons): Research personnel;250 or more employees;2.465
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total 2021;8.380
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Fewer than 250 employees;4.558
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;250 or more employees;2.806
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total 2021;7.364
Personnel in R&D in biotechnology (no. of persons). Women;Fewer than 250 employees;5.482
Personnel in R&D in biotechnology (no. of persons). Women;250 or more employees;3.242
Personnel in R&D in biotechnology (no. of persons). Women;Total 2021;8.725
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Fewer than 250 employees;3.094
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;250 or more employees;1.426
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total 2021;4.521
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Fewer than 250 employees;2.388
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;250 or more employees;1.816
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total 2021;4.204
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;7.354,4
Personnel in R&D in biotechnology (FTE);250 or more employees;4.168,8
Personnel in R&D in biotechnology (FTE);Total 2021;11.523,2
Personnel in R&D in biotechnology (FTE): Research personnel;Fewer than 250 employees;4.402,9
Personnel in R&D in biotechnology (FTE): Research personnel;250 or more employees;1.938,6
Personnel in R&D in biotechnology (FTE): Research personnel;Total 2021;6.341,6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Fewer than 250 employees;2.951,5
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;250 or more employees;2.230,1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total 2021;5.181,6
Personnel in R&D in biotechnology (FTE). Women;Fewer than 250 employees;3.909,3
Personnel in R&D in biotechnology (FTE). Women;250 or more employees;2.643,4
Personnel in R&D in biotechnology (FTE). Women;Total 2021;6.552,7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Fewer than 250 employees;2.305,8
Personnel in R&D in biotechnology (FTE). Women: Research personnel;250 or more employees;1.158,6
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total 2021;3.464,4
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Fewer than 250 employees;1.603,5
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;250 or more employees;1.484,8
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total 2021;3.088,3
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;648.976
Internal expenditure on R&D (thousands of euros);250 or more employees;388.911
Internal expenditure on R&D (thousands of euros);Total 2021;1.037.887
1) By nature of the expense: Current expenses;Fewer than 250 employees;577.758
1) By nature of the expense: Current expenses;250 or more employees;361.713
1) By nature of the expense: Current expenses;Total 2021;939.471
1.1) Remuneration to research personnel;Fewer than 250 employees;213.250
1.1) Remuneration to research personnel;250 or more employees;108.275
1.1) Remuneration to research personnel;Total 2021;321.525
1.2) Remuneration to technical and auxiliary personnel;Fewer than 250 employees;104.359
1.2) Remuneration to technical and auxiliary personnel;250 or more employees;90.297
1.2) Remuneration to technical and auxiliary personnel;Total 2021;194.656
1.3) Other current expenses;Fewer than 250 employees;260.148
1.3) Other current expenses;250 or more employees;163.141
1.3) Other current expenses;Total 2021;423.290
2) By nature of the expense: Capital expenses;Fewer than 250 employees;71.218
2) By nature of the expense: Capital expenses;250 or more employees;27.197
2) By nature of the expense: Capital expenses;Total 2021;98.416
2.1) Land and buildings;Fewer than 250 employees;8.904
2.1) Land and buildings;250 or more employees;1.246
2.1) Land and buildings;Total 2021;10.150
2.2) Equipment and instruments;Fewer than 250 employees;48.703
2.2) Equipment and instruments;250 or more employees;23.835
2.2) Equipment and instruments;Total 2021;72.538
2.3) Acquisition of specific R&D software;Fewer than 250 employees;3.749
2.3) Acquisition of specific R&D software;250 or more employees;1.963
2.3) Acquisition of specific R&D software;Total 2021;5.713
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;9.862
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;153
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2021;10.015
1.1) By origin of the funds: Own funds;Fewer than 250 employees;428.118
1.1) By origin of the funds: Own funds;250 or more employees;282.919
1.1) By origin of the funds: Own funds;Total 2021;711.037
1.2) By origin of the funds: From companies;Fewer than 250 employees;87.264
1.2) By origin of the funds: From companies;250 or more employees;34.331
1.2) By origin of the funds: From companies;Total 2021;121.595
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;81.113
1.3) By origin of the funds: Public Administration funds;250 or more employees;26.309
1.3) By origin of the funds: Public Administration funds;Total 2021;107.422
1.4) By origin of the funds: From Universities;Fewer than 250 employees;192
1.4) By origin of the funds: From Universities;250 or more employees;0
1.4) By origin of the funds: From Universities;Total 2021;192
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;1.543
1.5) By origin of the funds: From non profit private institutions;250 or more employees;9.213
1.5) By origin of the funds: From non profit private institutions;Total 2021;10.756
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;50.745
1.6) By origin of the funds: Foreign funds;250 or more employees;36.139
1.6) By origin of the funds: Foreign funds;Total 2021;86.884
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;77.001
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;68.440
Purchase of R&D services in biotechnology (thousands of euros);Total 2021;145.440
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;54.755
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;41.115
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total 2021;95.870
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;22.246
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;27.324
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total 2021;49.570
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;41,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;21,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2021;39,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;12,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2021;12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;18,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;14,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2021;18,5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;10,9
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;14,8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2021;11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;12,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2021;15,6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total 2021;16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16,3
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;13,9
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2021;16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;40,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;32,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2021;40
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;54,9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;43,4
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2021;53,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;21,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;18,8
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2021;21,5
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;22,8
% Companies with income of an international origin related to biotechnological activities;250 or more employees;16,4
% Companies with income of an international origin related to biotechnological activities;Total 2021;22,2
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;9,1
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,8
% Turnover representing income of an international origin related to biotechnological activities;Total 2021;1,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;57,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;78
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total 2021;65,5
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;42,1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;22
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total 2021;34,5
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;93,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;74,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total 2021;86,3
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;5,2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;23,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total 2021;12,2
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;0,5
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;2,1
% Income of an international origin related with activities according to the classification: Operating source abroad;Total 2021;1,1
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;0,6
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0
% Income of an international origin related with activities according to the classification: Other;Total 2021;0,4